Ozuriftamab vedotin

Ozuriftamab vedotin (BA3021), an antibody-drug conjugate (ADC), is a conditionally active biologic (CAB) anti-receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab (HY-145626) conjugated to VcMMAE (HY-15575) . Ozuriftamab vedotin has antitumor activities[1].

Product Specifications

CAS Number

[2460400-11-5]

Product Name Alternative

BA3021; Anti-ROR2 ADC; CAB-ROR2-ADC

UNSPSC

12352211

Target

Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ozuriftamab-vedotin.html

Purity

99.65

Smiles

[Ozuriftamabvedotin]

References & Citations

[1]Alan L. Ho, et al. Abstract PO-007: A phase 2 open-label study of conditionally active biologic, ozuriftamab vedotin (BA3021) in PD-1/L1 failure patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res (2023) 29 (18_Supplement) : PO-007.